ORCID as entered in ROS

Select Publications
2006, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition and metabolic parameters', Antiviral Therapy, 11, pp. L23 - L24
,2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines.', Human Vaccines, 2, pp. 134 - 136
,2006, 'Electrochemical impedance characteristics of Ta/Cu contact regions in polishing slurries used for chemical mechanical planarization of Ta and Cu: considerations of galvanic corrosion', CORROSION SCIENCE, 48, pp. 372 - 388, http://dx.doi.org/10.1016/j.corsci.2005.01.008
,2006, 'Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study', Antiviral Therapy, 11, pp. 409 - 419
,2006, 'Epilogue: Preparing for an influenza pandernic in Australia', Medical Journal of Australia, 185, pp. S80 - S80
,2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85
,2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, 7, pp. 105 - 111
,2006, 'Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals', AIDS Research and Human Retroviruses, 22, pp. 338 - 341
,2006, 'Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study', AIDS RESEARCH AND HUMAN RETROVIRUSES, 22, pp. 837 - 841, http://dx.doi.org/10.1089/aid.2006.22.837
,2006, 'Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials', HIV Clinical Trials, 7, pp. 125 - 141
,2006, 'The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era', CLINICAL TRIALS, 3, pp. 119 - 132
,2006, 'Therapeutic vaccination against HIV: current progress and future possibilities', Clinical Science, 110, pp. 59 - 71
,2006, 'Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.', Lancet, 368, pp. 287 - 298
,2005, 'Time resolved impedance spectroscopy as a probe of electrochemical kinetics: The ferro/ferricyanide redox reaction in the presence of anion adsorption on thin film gold', ELECTROCHIMICA ACTA, 50, pp. 5659 - 5672, http://dx.doi.org/10.1016/j.electacta.2005.03.043
,2005, 'Chemical factors for chemical-mechanical and electrochemical-mechanical planarization of silver examined using potentiodynamic and impedance measurements', MATERIALS CHEMISTRY AND PHYSICS, 89, pp. 345 - 353, http://dx.doi.org/10.1016/j.matchemphys.2004.09.011
,2005, 'Informed consent: Practices and views of investigators in a multinational clinical trial', IRB Ethics and Human Research, 27, pp. 13 - 18, http://dx.doi.org/10.2307/3564530
,2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387
,2005, 'Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38, pp. 156 - 162, http://journals.lww.com/jaids/Fulltext/2005/02010/Buffalo_Hump_Seen_in_HIV_Associated_Lipodystrophy.6.aspx
,2005, 'Chemical effects in chemical mechanical planarization of TaN: investigation of surface reactions in a peroxide-based alkaline slurry using Fourier transform impedance spectroscopy', MATERIALS LETTERS, 59, pp. 690 - 693, http://dx.doi.org/10.1016/j.matlet.2004.11.010
,2005, 'Clinically relevant breakpoints for virco (R) TYPE HIV-1 phenotypic resistance information', Antiviral Therapy, 10, pp. S39 - S39
,2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, 19, pp. 1325 - 1327
,2005, 'HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting', AIDS, 19, pp. 169 - 178
,2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, 191, pp. 1686 - 1696
,2005, 'Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors', Antiviral Therapy, 10, pp. L5 - L5
,2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143
,2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, 1, pp. 232 - 238, http://www.landesbioscience.com/journals/vaccines/emeryHV1-6.pdf
,2005, 'The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals', AIDS, 19, pp. 1393 - 1399
,2005, 'The quality of informed consent in a clinical research study in Thailand.', IRB, 27, pp. 9 - 17, https://www.ncbi.nlm.nih.gov/pubmed/15835065
,2004, 'Micronutrient supplementation increases genital tract shedding of HIV-1 in women - Results of a randomized trial', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 37, pp. 1657 - 1663, http://dx.doi.org/10.1097/00126334-200412150-00021
,2004, 'Chemical roles of peroxide-based alkaline slurries in chemical-mechanical polishing of Ta: investigation of surface reactions using time-resolved impedance spectroscopy', MATERIALS CHEMISTRY AND PHYSICS, 86, pp. 347 - 357, http://dx.doi.org/10.1016/j.matchemphys.2004.03.016
,2004, 'Voltammetric and amperometric analyses of electrochemical nucleation: electrodeposition of copper on nickel and tantalum', JOURNAL OF ELECTROANALYTICAL CHEMISTRY, 568, pp. 121 - 133, http://dx.doi.org/10.1016/j.jelechem.2004.01.012
,2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98
,2004, 'CD4 cell response to 3 doses of subcutaneous interleukin 2:Meta-analysis of 3 Vanguard studies', Clinical Infectious Diseases, 39, pp. 115 - 122
,2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56
,2004, 'Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN[gamma] or IL-12', Vaccine, 23, pp. 188 - 197, http://www.sciencedirect.com/science/article/B6TD4-4CN9FR0-5/2/aa9e52964e8dec8ad797d2f13a3a639e
,2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11
,2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy:randomised, double-blind, placebo-controlled trial', Lancet, 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5
,2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870
,2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, 9, pp. L46 - L46
,2004, 'Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 36, pp. 693 - 701
,2003, 'Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors', AIDS, 17, pp. 1889 - 1896, http://dx.doi.org/10.1097/00002030-200309050-00007
,2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004
,2003, 'Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations', Journal of Clinical Microbiology, 41, pp. 227 - 236, http://dx.doi.org/10.1128/JCM.41.1.227-236.2003
,2003, 'In situ AFM study of surface layer removal during copper CMP', ELECTROCHEMICAL AND SOLID STATE LETTERS, 6, pp. G91 - G94, http://dx.doi.org/10.1149/1.1576051
,2003, 'An objective case definition of lipodystrophy in HIV-infected adults: a case-control study', Lancet, 361, pp. 726 - 735
,2003, 'An objective lipodystrophy severity grading scale using the lipodystrophy case definition score', Journal of Acquired Immune Deficiency Syndrome, 33, pp. 571 - 576
,2003, 'Chemokine receptor genotype and response to interleukin-2 therapy in HIB-1-infected individuals', Clinical Immunology, 106, pp. 36 - 40
,2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261
,2003, 'HIV lipodystrophy case definition using artificial neural network modelling.', Antiviral Therapy, 8, pp. 435 - 441
,2003, 'HIV lipodystrophy: prevalence, severity and correlates of risk in Australia', HIV Medicine, 4, pp. 293 - 301
,